Eli Lilly said last night it will deny 340B Drug Pricing Program discounts to providers that do not meet its documentation ...

When hospitals overcharge insurers for drugs they bought at deep 340B discounts, taxpayers, employers, and insured patients ...

With post-pandemic Medicaid enrollments on the decline and expected to fall further, revenue cycle leaders warn that ...

The 340B program is criticized for generating revenue rather than solely aiding underinsured patients, impacting community providers and Medicare patients. Pharmaceutical companies face challenges ...

Drug manufacturers participating in the Section 340B Drug Pricing Program now face a significant new litigation risk under the False Claims Act (“FCA”). In a recent decision, Adventist Health System v ...

Unexpected windfall or fragile safety net? Affluent communities or vulnerable poor? Welfare check or supplemental provider program? Making sense of the latest 340B program study published by the ...

On July 31, the US Department of Health and Human Services’ (HHS) Health Resources and Services Administration (HRSA) announced the availability of a new pilot program altering how pharmaceutical ...

Pending legislation to expand providers’ access to discounted drugs has sparked strong lobbying campaigns for and against the ...

Nevada hospitals and clinics face challenges as drug manufacturers restrict access to a federal discount drug program, ...

Effective compliance now spans transaction eligibility, OPAIS synchronization, Medicaid exclusion validation, cost-report ...

A federal judge in Missouri has denied a request by AstraZeneca Pharmaceuticals LP to compel several nonparty hospitals and ...